Thymosin β4 and TB-500: Why the Fragment Is Not the Protein

TB-500 and thymosin β4 are routinely used as if they were interchangeable names for one substance. They are not, and conflating them makes a large body of literature harder to read than it needs to be.

The protein

Thymosin β4 is a 43-residue protein and one of the most abundant intracellular proteins in many cell types. Its best-characterised function is sequestering monomeric G-actin, which places it at the centre of actin cytoskeletal dynamics. Because actin polymerisation underlies cell migration, the protein appears throughout the cell-motility literature. See PubMed.

The fragment

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β4 — a short sequence containing the motif responsible for G-actin binding, not the full protein. The rationale for using the fragment is straightforward: it is far cheaper to synthesise than a 43-residue protein and it retains the actin-binding determinant.

What it does not retain is everything else. Thymosin β4 has reported activities that are not attributed to the actin-binding motif alone, and a fragment cannot be assumed to reproduce them. When a paper reports an effect of thymosin β4, that finding does not automatically transfer to TB-500, and the reverse is equally true.

Why this matters when reading papers

Search results for either term will return studies on both. Before citing a result, check which molecule was actually used and at what concentration — molar equivalence between a 43-residue protein and a short fragment is not the same as mass equivalence, and studies sometimes report one where the other is meant.

The actin-binding motif, and what a fragment keeps

The determinant at the centre of this is a short hexapeptide motif, LKKTET, sitting within the central helical region of thymosin β4. That motif is what contacts G-actin, and it is the reason a fragment containing it retains actin-sequestering activity at all. Synthetic peptides sold under the TB-500 name correspond to the region around this motif rather than to a single universally agreed sequence — which is precisely why the identity question below matters.

Thymosin β4 itself is intrinsically disordered in solution. It has no stable fold on its own and adopts helical structure only on binding actin. A short fragment is therefore not “the folded part” of the protein — there is no folded part. What the fragment carries is a linear recognition motif, and the surrounding residues modulate how well that motif is presented.

What the full protein does that a fragment cannot be assumed to

• Actin sequestration at scale. The intact protein is abundant enough intracellularly to act as a genuine buffer for the monomeric actin pool. A fragment supplied exogenously at micromolar concentrations is not doing the same job.
• Interactions outside the actin motif. Reported activities attributed to regions of the protein other than LKKTET do not transfer to a fragment that lacks those regions.
• Processing products. Thymosin β4 is itself cleaved in vivo into shorter products, notably the N-terminal tetrapeptide Ac-SDKP, which has its own literature. A synthetic fragment corresponding to the actin-binding region is not that molecule either.
• Charge and solubility behaviour. A 43-residue polyanionic protein and a short cationic-leaning fragment do not behave alike in a buffer, on a column, or against plasticware.

Reading the literature without conflating the two

Almost every practical problem in this area comes from a search returning both molecules under one heading. Four checks resolve it:

• Identify the molecule in the methods, not the title. Papers frequently say “Tβ4” in the abstract and specify a synthetic fragment in the methods, or the reverse.
• Check the stated sequence and length. A 43-residue protein and a fragment of a dozen or so residues are different entities; the paper should state which.
• Convert concentrations properly. Molar and mass concentrations diverge by roughly a factor of three or four between the protein and a short fragment. A study reporting micrograms per millilitre is not directly comparable to one reporting micromolar unless you do the arithmetic.
• Note the source. Recombinant protein, chemically synthesised protein and synthetic fragment carry different impurity profiles — endotoxin in particular is a live question for recombinant material and not for solid-phase synthesis.

Sequence ambiguity under one trade name

This is the single most consequential practical point on this page. “TB-500” is a commercial designation, not a defined chemical name, and material circulating under it varies in length and in whether the N-terminus is acetylated. Two vials from two suppliers can both be labelled TB-500 and contain peptides of different mass.

The consequence is that a certificate reporting only a purity percentage is insufficient here. Mass confirmation against a stated sequence is what establishes which fragment you actually have, and without a stated sequence on the certificate, the mass has nothing to be checked against. When comparing suppliers, compare the sequences, not the names. Nomenclature conventions across analogs and fragments are covered in peptide nomenclature.

Assays used in this area

If the question is whether a given fragment behaves as expected, these are the readouts that answer it.

• Pyrene-actin polymerisation. The standard biochemical assay. Fluorescently labelled G-actin increases in signal on polymerisation; a sequestering agent slows or reduces the plateau. Gives a direct, cell-free measure of actin binding.
• Sedimentation assays. Ultracentrifugation separates F-actin from G-actin; the ratio reports sequestration without a fluorophore.
• Isothermal titration calorimetry or fluorescence anisotropy for binding affinity to G-actin directly.
• Scratch and transwell migration assays in cell culture, where migration is the downstream readout. Useful but several inferential steps removed from the binding event, and sensitive to proliferation as a confounder — a proliferation control belongs in the design.
• Circular dichroism to confirm the disorder-to-helix transition on actin binding, where the mechanism itself is in question.

Whichever is chosen, an intact thymosin β4 comparator arm is what makes a fragment result interpretable. Without it, the study measures the fragment against nothing.

Analytical characterisation

• Mass confirmation against a stated sequence — the priority for this compound, for the reasons above. ESI-MS or MALDI-TOF against the calculated mass, with acetylation accounted for if present.
• RP-HPLC purity with the gradient, column and wavelength stated. Deletion sequences differing by one residue elute close to the main peak and hide under a steep gradient.
• Net peptide content. Lyophilised material carries counterions and residual water; gross vial mass overstates peptide mass by commonly fifteen to twenty-five percent. See net peptide content explained.
• Counterion identity. Residual trifluoroacetate has its own activity in cell assays — relevant here because migration assays are cell-based. See counterions and salt form.
• Endotoxin is not established by HPLC or MS. If the readout is immune or inflammatory, it needs its own test. See endotoxin and sterility.

Handling and storage

Short, largely hydrophilic peptides of this type reconstitute readily in water or a near-neutral buffer and are unremarkable to handle, with three caveats. Aliquot on reconstitution so no tube is thawed twice — repeated freeze–thaw cycles promote aggregation and adsorption losses that lower effective concentration invisibly. Use low-binding plasticware at low working concentrations. And treat solution age, not vial age, as the variable that governs fitness for use. Conditions are in storage and stability; documentation in keeping a peptide inventory.

On the blends

TB-500 is frequently supplied blended with BPC-157. For experimental purposes a blend is a single formulation with two variables in it, and any result from a blend is attributable to neither component individually without single-agent arms. The stated split matters too — a 10mg blend at 5mg + 5mg and a 20mg blend at 10mg + 10mg are different concentrations of each component, not simply more of the same thing. The limits of what the BPC-157 literature actually supports are set out in BPC-157 and the limits of the published literature.

Terms used here

• Thymosin β4 (Tβ4) — 43-residue intracellular protein; principal G-actin sequestering protein in many cell types.
• TB-500 — commercial designation for synthetic peptides corresponding to the actin-binding region; not a defined sequence.
• LKKTET — the hexapeptide motif responsible for G-actin binding.
• G-actin / F-actin — monomeric and filamentous actin respectively.
• Sequestration — binding monomer so it is unavailable for polymerisation, as distinct from capping or severing filaments.
• Intrinsically disordered — no stable fold in isolation; structure adopted on binding a partner.
• Ac-SDKP — N-terminal tetrapeptide processing product of thymosin β4, with a separate literature.

Analytical note

Because TB-500 is a defined short sequence, mass spectrometry gives an unambiguous identity confirmation. That is worth checking on a certificate: several actin-binding-region fragments of differing length are in circulation under the same trade name, and they are not the same molecule. Our note on why certificates disagree covers what else to look for.

Products: TB-500 5mg, TB-500 10mg, TB-500 and BPC-157 blend.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.